Type: advantage counterplan. It does not insure anyone. It captures a cost advantage through market structure and links to none of the topic’s rate-setting disadvantages. Knowing that decides which affirmatives you read it against.
Wording the Counterplan
Three planks. Increase FTC funding. Amend the Hart-Scott-Rodino Act to lower the merger notification threshold to $50 million. Amend Sections 4 and 5 of the FTC Act to cover 501(c)(3) charities and nonprofit organizations.
The third plank is the smart one and most debaters will not know why. The FTC Act’s core prohibitions reach entities organized for profit. A large share of American hospital systems — including many of the largest and most consolidated — are nonprofits, which puts them substantially outside Section 5 authority. That is a real jurisdictional gap in current antitrust law, not a debate contrivance, and closing it is what makes this more than a funding increase.
The Hart-Scott-Rodino plank does the complementary work: lowering the notification threshold catches the small and mid-size acquisitions — physician practices, regional facilities — that aggregate into local market dominance without individually triggering review. That is where healthcare consolidation actually happens.
Explain both in the 2NC. A judge who understands the nonprofit gap evaluates this counterplan very differently.
Competition
Weak, and you should know that going in. The counterplan does not do the plan and does not exclude it. Against a coverage affirmative, nothing prevents doing both — which is why the permutation is the affirmative’s first and best move.
Competition is functional and depends on the net benefit doing the work: the plan triggers a disadvantage, the counterplan does not, and the permutation includes the plan. That is net-benefit competition, which is legitimate but weaker than textual competition, and an affirmative that beats the net benefit has beaten competition at the same time.
Against an affirmative with a rate-setting mandate, competition is cleaner — you compete on that mandate specifically. Say which affirmative you are hitting before you decide how to frame it.
Net Benefits
The counterplan attacks costs through market structure rather than price regulation, so no rate-setting means no doctors disadvantage, no monopsony means no pharma disadvantage, and no coverage expansion means a negligible spending link. Among the counterplans here it is the cleanest version of that trade.
The turn is better than the deficit and should lead the block: the plan cannot solve hospital price gouging and may actively spur mergers, because providers consolidate to gain bargaining power against a large public payer. That is offense, not defense.
Check the counterplan against your own net benefit. The affirmative section of this file lists “links to the net benefit” twice, which tells you the lab expects it. Increased federal enforcement links to some spending and politics positions.
Answering the Permutation
Perm do both is the round. The affirmative’s version — “only the perm solves coverage” — is correct on its face, because the counterplan insures nobody.
Your answer is the merger-inducement turn: if the plan causes consolidation, doing both spends the FTC’s enhanced capacity chasing mergers the plan created, so the permutation is worse than the counterplan alone. That is the only response that reaches a permutation this clean, and it has to be won on the link.
Perm do the counterplan is unavailable in the usual sense — the affirmative cannot advocate antitrust reform as the plan, because it is not national health insurance. Say so; it is a free topicality-flavored argument.
Perm do the plan and the nonprofit plank is the permutation to expect from a good affirmative, and the file does not block it. Closing the FTC Act gap is severable from the funding and threshold planks and does not obviously trade off with anything. Answer on intrinsicness if they add enforcement capacity the counterplan supplied; otherwise concede the plank and argue the remaining differential still carries the net benefit.
For the affirmative: do-both is your best and it is close to unanswerable against a coverage advantage. Lead with it and spend the rest of your time on the net benefit.
Solvency Deficits
The cost deficit — antitrust does not lower costs enough or fast enough — gets answered on the price internal link: prices are the only internal link that matters, and consolidated hospitals raise prices. Force the affirmative to defend a cost mechanism that is not about prices.
Strikedown and lobbying are the affirmative’s better arguments. The file’s answer is that healthcare antitrust has support across the administration, the courts, and the FTC itself, which is unusual alignment worth extending.
The refunding plank answers most enforcement-capacity deficits at once — the file’s framing that all the affirmative’s deficits depend on insufficient status quo funding is accurate and collapses several answers into one.
Timeframe is the deficit that sticks. Merger review, litigation, appeals, and divestiture run on a multi-year clock, and market structure changes slowly even after a successful case. Against an affirmative with people losing coverage now, you lose the timeframe comparison and cannot fiat faster courts.
Theory
Advantage counterplans draw the mildest objections in debate and this one is textbook. No PIC, no process, no agent shift, and it has a solvency advocate.
The one live argument is that an advantage counterplan competing only off a net benefit is functionally a disadvantage with a counterplan attached, which some affirmatives run as a conditionality or “not a real counterplan” argument. It rarely wins. If the affirmative goes for theory here they have misallocated, and you should say so.
